Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NTRK1 - KHDRBS1||sarcoma||predicted - sensitive||Crizotinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with unclassified mesenchymal sarcoma harboring NTRK1-KHDRBS1 achieved a complete response after 3 months of Xalkori (crizotinib) treatment and remained on therapy and progression free at 45 months (PMID: 33941195).||33941195|